Canada: Pharmacapsules@Gowlings – February 2006

Last Updated: March 23 2006

Edited by Adrienne Blanchard and Jennifer Wilkie


  • Transfer Pricing Issues
  • Quebec Denies Certification Of Pharmaceutical Class Action
  • PMPRB Announces Increased Enforcement Activities
  • Cancer Drug Access And The Canada Health Act
  • Proposed Changes To U.S. Patent Rule Not Welcomed By Biotech Industry
  • Online Pharmacists Seek Clean Slate With New Conservative Government
  • Release Of Draft Guidance Document For Drug Submissions In Electronic Format
  • Recent Cases

Transfer Pricing Issues

Possible consequences of several recent changes (particularly those in Canada) to the allowed profitability of R&D activities are considered by Dr. Jamal Hejazi, member of the Gowlings Transfer Pricing Goup, in the article, "Transfer Pricing Within the North American Pharmaceutical Industry: Has There Been a Structural Shift in Risk?". Considering the focus on the alleged profitability of e.g. marketing and distribution activities, Dr. Hejazi states his reasons for fearing that the high returns for R&D activities, needed to make their business a success, are being diminished.

The full text of the article can be seen on Gowlings website.

For more information on transfer pricing issues, please contact Gowlings' Chief Economist, Jamal Hejazi Ph.D.

Quebec Denies Certification Of Pharmaceutical Class Action

On January 17, 2006, the Quebec Superior Court refused to authorize a class action in a case that was brought based on information reported in an article printed in La Presse. Justice Roy held that despite the amendments made in 2003 to the Code of Civil Procedure (CCP) intended to reduce the criteria for instituting a class action suit, there is still a minimal factual foundation that must be demonstrated to a Court before it can authorize a class action.

The case began in February 2003, when a proposed class action was filed against several generic pharmaceutical manufacturers for allegedly giving out "illegal" rebates and other benefits to pharmacists in Quebec and other provinces. The suit was based on information contained in La Presse.

Justice Roy's decision re-establishes a balance between the amendments to the CCP in January 2003, which lessen a petitioner's burden to provide evidence in support of a certification motion, and the requirement to include precise and sufficient facts to allow a Court to determine whether the requirements for instituting a class action have been meet.

For more information, please see:

Also, please see the judgment in Option Consommateurs et al. c. Novopharm Ltd. et al., 2006 QCCS 118 (in French)

PMPRB Announces Increased Enforcement Activities

The PMPRB signalled in its January 2006 Newsletter that there will be increased enforcement activities. As recent evidence of this, one can point to the hearing notices that issued in respect of two drugs during the month of January.

The January 2006 Newsletter also reviews the Federal Court decision in Hoechst Marion Roussel Canada Inc. v. Attorney General of Canada. The Federal Court held that, as a patent application only gives rise to a potential grant of a patent, the PMPRB is not authorized to assert jurisdiction over a medicine until a patent is issued. However, the PMPRB comments in its newsletter:

"Patentees will be interested to know that the HMRC decision does not affect the Board's present policy on patent pending, which is to assert jurisdiction retroactively to review the price at which the medicine was sold during the pre-grant infringement period, once the patent issues".

The January 2006 Newsletter also reports on:

  • the PMPRB's new initiative to monitor and report on non-patented drug prices; and
  • voluntary compliance undertakings that were accepted in the last quarter relating to two separate drugs

To access the Newsletter, please see:

Cancer Drug Access And The Canada Health Act

In its Annual Report Card, the Cancer Advocacy Coalition of Canada (CACC) examined cancer drug access across Canada, posing the question does cancer drug treatment comply with the principles of the Canada Health Act, namely, universality, comprehensiveness, accessibility, portability and public administration.

The Canada Health Act mandates coverage of hospital and physician services but not drug coverage. Historically, when cancer treatment consisted of in-patient chemotherapy and radiation, treatment was covered under hospital budgets. As a result of the shift of cancer treatment from an in-patient to an out-patient environment, each province has employed its own process for providing for cancer drug treatments. These include payment through cancer agency and hospital budgets, provincial and private insurance plans, patient payment options and pharmaceutical company sponsored payment assistance programs.

In its study, the CACC identified 24 recently approved drugs, along with evidence supporting their use, and then assessed the availability of these drugs in each province. The results ranged from 21 of the 24 drugs being approved for funding in British Columbia to only 4 of the drugs being approved for funding in Prince Edward Island. Ontario, Alberta and Quebec had approved funding for 6, 7, and 14 of the drugs respectively. In addition to the drugs approved for funding, all of the provinces also allowed some type of limited access to at least one additional drug, to a maximum of 13 of the 24 drugs in Ontario.

The authors conclude that "evaluated on the guiding principles of the Canada Health Act, new cancer drugs are not accessible to all patients that require them, or universal in their coverage, or comprehensive in their integration with other cancer treatments, or portable from province to province, or even publicly funded."

To ensure more timely access to cancer drug treatments, the CACC has issued recommendations which include:

- establishing a national catastrophic drug strategy;
- developing Canadian wide guidelines for cancer drug treatment;
- increasing research to establish which patients would best benefit from new therapies; and
- incorporating patient choice into decision-making.

The CACC Report Card 2005 is available at:

Proposed changes to U.S. Patent rule not welcomed by biotech industry

Although the proposed amendments to the U.S. federal patent rules may alleviate the backlog of patent applications waiting review by examiners, biotech leaders warn that these amendments will have a crippling effect on their industry. The new rule seeks to limit the number of continuation applications to one, as well as limit the number of claims for any subsequent applications to 10.

According to Todd Gillenwater, vice-president of public policy at the California Healthcare Institute, the proposed amendments may result in devastating consequences. "The biotech patent process not only concerns the product itself but also the process to make the product. As you go through 12-15 year cycle, you learn matters about the product, process and its ultimate application – all would require revisiting that application. If you restrict continuing applications, it will force the industry to file overly broad patents to catch everything."

Advocates for the changes state that the amendments will reduce the backlog at the U.S. Patent Office as well as address the issue of abuse in the present patent system. "Continuous applications are sometimes used by less scrupulous companies to claim competitors' technologies in add-on filings while maintaining their priority date on the invention, a practice referred to in the industry as a "submarine patent".

For more information, please see:

Online Pharmacists Seek Clean Slate With New Conservative Government

Having lived for over a year in fear of a crackdown on cross-border trade by the previous Liberal government, the online pharmacy industry is looking forward to starting anew with the newly elected Conservative government.

There remains concern, however, that the newly elected government will not give the issue the same priority as the previous Liberal government.

Just prior to the fall of the previous Liberal government, former health minister Ujjal Dosanjh introduced a bill that was also supported by the Conservatives which that would provide the ability to ban the bulk export of drugs to the U.S.

For more information, please see:

Release Of Draft Guidance Document For Drug Submissions In Electronic Format

By a notice dated January 25, 2006, Health Canada has released a draft guidance document for comment within a 60 day consultation period. The guidance document will assist sponsors in the preparation of drug submissions in the electronic Common Technical Document (eCTD) format developed by the ICH of Technical Requirements for Registration of Pharmaceuticals for Human Use.

The document defines three types of filing formats for drug submissions in eCTD format: co-submission, hybrid submission and electronic-only submission. It also contains information on pilot implementation of the hybrid filing format set to begin on June 30, 2006. It is indicated that the guidance document reflects comments received from stake-holders, including industry representatives, and is expected to be modified upon completion of the 60 day consultation and further, that there may be subsequent iterations of the draft.

Since September 1, 2004, Health Canada has accepted submissions in the eCTD format along with full paper based submissions (known as a co-submission format of filing). At this stage, Health Canada is entering into a transition plan that will eventually accept submissions in the electronic only submission format.

Any comments or questions regarding the draft guidance document should be submitted no later than March 31, 2006.

For information please see the following link:

Recent Cases

Syntex Pharmaceuticals International Limited v. Canada, December 12, 2005, s. 8 proceeding

- the defendant appealed an order striking out a third party notice joining the Crown as a third party to the plaintiff's claim for damages under s. 8 of the NOC Regulations.

- the Court of Appeal held that there could be a claim in negligence against the Crown and proof of a statutory breach that causes damages may be evidence of such negligence, however, the defendants have not properly plead a valid cause of action in negligence

- thus, the appeal was allowed, and although the current pleading was struck, leave was granted to file an amended third party notice.

For the text of this decision, please see:

AstraZeneca AB v. Apotex Inc., January 18, 2006, s. 55.2 proceeding

- prohibition denied

- the Applicant argued issue estoppel in relation to the respondent's formulation, however, as this issue was not plead in the Notice of Application, the argument was rejected.

- after construing the patent, it was determined that the respondent's tablets would not infringe.

- the invalidity allegations were not considered by the Court.

For the text of this decision, please see:

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions